{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T22:12:16Z","timestamp":1793052736341,"version":"4.5.0"},"reference-count":216,"publisher":"Bentham Science Publishers Ltd.","issue":"16","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDT"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:sec>\n<jats:title>Abstract:<\/jats:title>\n<jats:p>Now-a-days fungal infection emerges as a significant problem to healthcare management systems due to high frequency of associated morbidity, mortality toxicity, drug-drug interactions, and resistance of the antifungal agents. Aspergillus is the most common mold that cause infection in immunocompromised hosts. It's a hyaline mold that is cosmopolitan and ubiquitous in nature. Aspergillus infects around 10 million population each year with a mortality rate of 30-90%. Clinically available antifungal formulations are restricted to four classes (i.e., polyene, triazole, echinocandin, and allylamine), and each of them have their own limitations associated with the activity spectrum, the emergence of resistance, and toxicity. Consequently, novel antifungal agents with modified and altered chemical structures are required to combat these invasive fungal infections. To overcome these limitations, there is an urgent need for new antifungal agents that can act as potent drugs in near future. Currently, some compounds have shown effective antifungal activity. In this review article, we have discussed all potential antifungal therapies that contain old antifungal drugs, combination therapies, and recent novel antifungal formulations, with a focus on the Aspergillus associated infections.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1389450123666220623164548","type":"journal-article","created":{"date-parts":[[2022,6,24]],"date-time":"2022-06-24T11:58:04Z","timestamp":1656071884000},"page":"1465-1488","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Therapeutic Approaches for Combating Aspergillus Associated Infection"],"prefix":"10.2174","volume":"23","author":[{"given":"Anil K.","family":"Chhillar","sequence":"first","affiliation":[{"name":"Department of Biotechnology, Maharishi Dayanand University, Rohtak, Haryana 124001, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aruna","family":"Punia","sequence":"additional","affiliation":[{"name":"Department of Biotechnology, Maharishi Dayanand University, Rohtak, Haryana 124001, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pooja","family":"Choudhary","sequence":"additional","affiliation":[{"name":"Department of Biotechnology, Maharishi Dayanand University, Rohtak, Haryana 124001, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Namita","family":"Sharma","sequence":"additional","affiliation":[{"name":"Department of Biotechnology, Maharishi Dayanand University, Rohtak, Haryana 124001, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sweety","family":"Dahiya","sequence":"additional","affiliation":[{"name":"Department of Biotechnology, Maharishi Dayanand University, Rohtak, Haryana 124001, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prity","family":"Gulia","sequence":"additional","affiliation":[{"name":"Department of Biotechnology, Maharishi Dayanand University, Rohtak, Haryana 124001, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1159\/000489474","volume":"96","author":"Alastruey-Izquierdo A.","year":"2018","unstructured":"Alastruey-Izquierdo A.; Cadranel J.; Flick H.; Treatment of chronic pulmonary aspergillosis: Current standards and future perspectives. Respiration 2018,96(2),159-170","journal-title":"Respiration"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"e171312","DOI":"10.3201\/eid2408.171312","volume":"24","author":"Denning D.W.","year":"2018","unstructured":"Denning D.W.; Page I.D.; Chakaya J.; Case definition of chronic pulmonary aspergillosis in resource-constrained settings. Emerg Infect Dis 2018,24(8),e171312","journal-title":"Emerg Infect Dis"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1086\/651263","volume":"50","author":"Kontoyiannis D.P.","year":"2010","unstructured":"Kontoyiannis D.P.; Marr K.A.; Park B.J.; Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: Overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis 2010,50(8),1091-1100","journal-title":"Clin Infect Dis"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1111\/myc.12628","volume":"60","author":"Cornely O.A.","year":"2017","unstructured":"Cornely O.A.; Lass-Fl\u00f6rl C.; Lagrou K.; Arsic-Arsenijevic V.; Hoenigl M.; Improving outcome of fungal diseases - Guiding experts and patients towards excellence. Mycoses 2017,60(7),420-425","journal-title":"Mycoses"},{"key":"ref=5","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1080\/13693780802139859","volume":"47","author":"Geiser D.M.","year":"2009","unstructured":"Geiser D.M.; Sexual structures in Aspergillus: Morphology, importance and genomics. Med Mycol 2009,47,S21-S26","journal-title":"Med Mycol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.ccm.2017.04.003","volume":"38","author":"Carmona E.M.","year":"2017","unstructured":"Carmona E.M.; Limper A.H.; Overview of treatment approaches for fungal infections. Clin Chest Med 2017,38(3),393-402","journal-title":"Clin Chest Med"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"3329","DOI":"10.1128\/AAC.00345-07","volume":"51","author":"Meletiadis J.","year":"2007","unstructured":"Meletiadis J.; Antachopoulos C.; Stergiopoulou T.; Pournaras S.; Roilides E.; Walsh T.J.; Differential fungicidal activities of amphotericin B and voriconazole against Aspergillus species determined by microbroth methodology. Antimicrob Agents Chemother 2007,51(9),3329-3337","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"3098","DOI":"10.1038\/s41467-018-05497-7","volume":"9","author":"Gei\u00dfel B.","year":"2018","unstructured":"Gei\u00dfel B.; Loiko V.; Klugherz I.; Azole-induced cell wall carbohydrate patches kill Aspergillus fumigatus. Nat Commun 2018,9(1),3098","journal-title":"Nat Commun"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1111\/jphp.12780","volume":"69","author":"Patil A.","year":"2017","unstructured":"Patil A.; Majumdar S.; Echinocandins in antifungal pharmacotherapy. J Pharm Pharmacol 2017,69(12),1635-1660","journal-title":"J Pharm Pharmacol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1164\/rccm.201407-1275OC","volume":"190","author":"Prattes J.","year":"2014","unstructured":"Prattes J.; Flick H.; Pr\u00fcller F.; Novel tests for diagnosis of invasive aspergillosis in patients with underlying respiratory diseases. Am J Respir Crit Care Med 2014,190(8),922-929","journal-title":"Am J Respir Crit Care Med"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1086\/505870","volume":"43","author":"Cornillet A.","year":"2006","unstructured":"Cornillet A.; Camus C.; Nimubona S.; Comparison of epidemiological, clinical, and biological features of invasive aspergillosis in neutropenic and nonneutropenic patients: A 6-year survey. Clin Infect Dis 2006,43(5),577-584","journal-title":"Clin Infect Dis"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/2047-783X-16-4-153","volume":"16","author":"Mayr A.","year":"2011","unstructured":"Mayr A.; Lass-Fl\u00f6rl C.; Epidemiology and antifungal resistance in invasive Aspergillosis according to primary disease: Review of the literature. Eur J Med Res 2011,16(4),153-157","journal-title":"Eur J Med Res"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1093\/mmy\/myw060","volume":"55","author":"Osherov N.","year":"2017","unstructured":"Osherov N.; Kontoyiannis D.P.; The anti-Aspergillus drug pipeline: Is the glass half full or empty? Sabouraudia 2017,55(1),118-124","journal-title":"Sabouraudia"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/nchembio.1205","volume":"9","author":"Roemer T.","year":"2013","unstructured":"Roemer T.; Boone C.; Systems-level antimicrobial drug and drug synergy discovery. Nat Chem Biol 2013,9(4),222-231","journal-title":"Nat Chem Biol"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1128\/CMR.12.2.310","volume":"12","author":"Latg\u00e9 J-P.","year":"1999","unstructured":"Latg\u00e9 J-P.; Aspergillus fumigatus and aspergillosis. Clin Microbiol Rev 1999,12(2),310-350","journal-title":"Clin Microbiol Rev"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"3080","DOI":"10.1128\/iai.65.8.3080-3085.1997","volume":"65","author":"Debeaupuis J-P.","year":"1997","unstructured":"Debeaupuis J-P.; Sarfati J.; Chazalet V.; Latg\u00e9 J-P.; Genetic diversity among clinical and environmental isolates of Aspergillus fumigatus. Infect Immun 1997,65(8),3080-3085","journal-title":"Infect Immun"},{"key":"ref=17","first-page":"42","volume":"4","author":"W\u00e9ry N.","year":"2014","unstructured":"W\u00e9ry N.; Bioaerosols from composting facilities-a review. Front Cell Infect Microbiol 2014,4,42","journal-title":"Front Cell Infect Microbiol"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1186\/s12866-016-0859-4","volume":"16","author":"Gonz\u00e1lez-Ram\u00edrez A.I.","year":"2016","unstructured":"Gonz\u00e1lez-Ram\u00edrez A.I.; Ram\u00edrez-Granillo A.; Medina-Canales M.G.; Rodr\u00edguez-Tovar A.V.; Mart\u00ednez-Rivera M.A.; Analysis and description of the stages of Aspergillus fumigatus biofilm formation using scanning electron microscopy. BMC Microbiol 2016,16(1),243","journal-title":"BMC Microbiol"},{"key":"ref=19","first-page":"2","volume":"52","author":"Kaur S.","year":"2014","unstructured":"Kaur S.; Singh S.; Biofilm formation by Aspergillus fumigatus. Med Mycol 2014,52(1),2-9","journal-title":"Med Mycol"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.anai.2017.07.008","volume":"119","author":"Masaki K.","year":"2017","unstructured":"Masaki K.; Fukunaga K.; Matsusaka M.; Characteristics of severe asthma with fungal sensitization. Ann Allergy Asthma Immunol 2017,119(3),253-257","journal-title":"Ann Allergy Asthma Immunol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s13601-020-00353-8","volume":"10","author":"Rapeport W.G.","year":"2020","unstructured":"Rapeport W.G.; Ito K.; Denning D.W.; The role of antifungals in the management of patients with severe asthma. Clin Transl Allergy 2020,10(1),46","journal-title":"Clin Transl Allergy"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1183\/09031936.06.00074705","volume":"27","author":"Denning D.W.","year":"2006","unstructured":"Denning D.W.; O\u2019Driscoll B.R.; Hogaboam C.M.; Bowyer P.; Niven R.M.; The link between fungi and severe asthma: A summary of the evidence. Eur Respir J 2006,27(3),615-626","journal-title":"Eur Respir J"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s11882-011-0217-4","volume":"11","author":"Agarwal R.","year":"2011","unstructured":"Agarwal R.; Severe asthma with fungal sensitization. Curr Allergy Asthma Rep 2011,11(5),403-413","journal-title":"Curr Allergy Asthma Rep"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"165rv13-165rv13","DOI":"10.1126\/scitranslmed.3004404","volume":"4","author":"Brown GD","year":"2012","unstructured":"Brown GD; Denning DW; Gow NAR; Levitz SM; Netea MG; White TC; Hidden killers: Human fungal infections. Sci Transl Med 2012,4(165),165rv13-165rv13","journal-title":"Sci Transl Med"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"4254","DOI":"10.1016\/j.jaip.2021.08.038","volume":"9","author":"Mistry H.","year":"2021","unstructured":"Mistry H.; Ajsivinac Soberanis H.M.; Kyyaly M.A.; The clinical implications of Aspergillus fumigatus sensitization in difficult-to-treat asthma patients. J Allergy Clin Immunol Pract 2021,9(12),4254-4267","journal-title":"J Allergy Clin Immunol Pract"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1111\/cea.12141","volume":"43","author":"Agarwal R.","year":"2013","unstructured":"Agarwal R.; Chakrabarti A.; Shah A.; Allergic bronchopulmonary aspergillosis: Review of literature and proposal of new diagnostic and classification criteria. Clin Exp Allergy 2013,43(8),850-873","journal-title":"Clin Exp Allergy"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1136\/thoraxjnl-2014-206291","volume":"70","author":"Kosmidis C.","year":"2015","unstructured":"Kosmidis C.; Denning D.W.; The clinical spectrum of pulmonary aspergillosis. Thorax 2015,70(3),270-277","journal-title":"Thorax"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1182\/blood-2015-05-645986","volume":"126","author":"Price T.H.","year":"2015","unstructured":"Price T.H.; Boeckh M.; Harrison R.W.; Efficacy of transfusion with granulocytes from G-CSF\/dexamethasone-treated donors in neutropenic patients with infection. Blood 2015,126(18),2153-2161","journal-title":"Blood"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s00281-014-0471-3","volume":"37","author":"Vacher G.","year":"2015","unstructured":"Vacher G.; Niculita-Hirzel H.; Roger T.; Immune responses to airborne fungi and non-invasive airway diseases. Semin Immunopathol 2015,37,83-96","journal-title":"Semin Immunopathol"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/nature07528","volume":"457","author":"O\u2019Gorman C.M.","year":"2009","unstructured":"O\u2019Gorman C.M.; Fuller H.; Dyer P.S.; Discovery of a sexual cycle in the opportunistic fungal pathogen Aspergillus fumigatus. Nature 2009,457(7228),471-474","journal-title":"Nature"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"67","DOI":"10.3114\/sim.2007.59.08","volume":"59","author":"Pitt J.I.","year":"2007","unstructured":"Pitt J.I.; Samson R.A.; Nomenclatural considerations in naming species of Aspergillus and its teleomorphs. Stud Mycol 2007,59,67-70","journal-title":"Stud Mycol"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1111\/j.1574-6976.2011.00308.x","volume":"36","author":"Dyer P.S.","year":"2012","unstructured":"Dyer P.S.; O\u2019Gorman C.M.; Sexual development and cryptic sexuality in fungi: Insights from Aspergillus species. FEMS Microbiol Rev 2012,36(1),165-192","journal-title":"FEMS Microbiol Rev"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.jaci.2009.06.011","volume":"124","author":"Gergen P.J.","year":"2009","unstructured":"Gergen P.J.; Arbes S.J.; Calatroni A.; Mitchell H.E.; Zeldin D.C.; Total IgE levels and asthma prevalence in the US population: Results from the National Health and Nutrition Examination Survey 2005-2006. J Allergy Clin Immunol 2009,124(3),447-453","journal-title":"J Allergy Clin Immunol"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"361","DOI":"10.3109\/13693786.2012.738312","volume":"51","author":"Denning D.W.","year":"2013","unstructured":"Denning D.W.; Pleuvry A.; Cole D.C.; Global burden of allergic bronchopulmonary aspergillosis with asthma and its complication chronic pulmonary aspergillosis in adults. Med Mycol 2013,51(4),361-370","journal-title":"Med Mycol"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/j.jaip.2014.08.007","volume":"2","author":"Greenberger P.A.","year":"2014","unstructured":"Greenberger P.A.; Bush R.K.; Demain J.G.; Luong A.; Slavin R.G.; Knutsen A.P.; Allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol Pract 2014,2(6),703-708","journal-title":"J Allergy Clin Immunol Pract"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.3389\/fmicb.2018.01810","volume":"9","author":"Takazono T.","year":"2018","unstructured":"Takazono T.; Izumikawa K.; Recent advances in diagnosing chronic pulmonary aspergillosis. Front Microbiol 2018,9,1810","journal-title":"Front Microbiol"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/ciw326","volume":"63","author":"Patterson T.F.","year":"2016","unstructured":"Patterson T.F.; Thompson G.R.; Denning D.W.; Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis 2016,63(4),e1-e60","journal-title":"Clin Infect Dis"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1183\/13993003.00583-2015","volume":"47","author":"Denning D.W.","year":"2016","unstructured":"Denning D.W.; Cadranel J.; Beigelman-Aubry C.; Chronic pulmonary aspergillosis: Rationale and clinical guidelines for diagnosis and management. Eur Respir J 2016,47(1),45-68","journal-title":"Eur Respir J"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1007\/s12281-017-0304-7","volume":"11","author":"Maghrabi F.","year":"2017","unstructured":"Maghrabi F.; Denning D.W.; The management of chronic pulmonary aspergillosis: The UK national aspergillosis centre approach. Curr Fungal Infect Rep 2017,11(4),242-251","journal-title":"Curr Fungal Infect Rep"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.bbmt.2018.09.028","volume":"25","author":"Robin C.","year":"2019","unstructured":"Robin C.; Cordonnier C.; Sitbon K.; Mainly post-transplant factors are associated with invasive aspergillosis after allogeneic stem cell transplantation: A study from the Surveillance des Aspergilloses Invasives en France and Soci\u00e9t\u00e9 Francophone de Greffe de Moelle et de Th\u00e9rapie Cellulaire. Biol Blood Marrow Transplant 2019,25(2),354-361","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1111\/j.1469-0691.2011.03548.x","volume":"17","author":"Lortholary O.","year":"2011","unstructured":"Lortholary O.; Gangneux J-P.; Sitbon K.; Epidemiological trends in invasive aspergillosis in France: The SAIF network (2005-2007). Clin Microbiol Infect 2011,17(12),1882-1889","journal-title":"Clin Microbiol Infect"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s15010-013-0539-3","volume":"42","author":"Montagna M.T.","year":"2014","unstructured":"Montagna M.T.; Lovero G.; Coretti C.; SIMIFF study: Italian fungal registry of mold infections in hematological and non-hematological patients. Infection 2014,42(1),141-151","journal-title":"Infection"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1097\/00005792-200007000-00006","volume":"79","author":"Patterson T.F.","year":"2000","unstructured":"Patterson T.F.; Kirkpatrick W.R.; White M.; Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus study group. Medicine (Baltimore) 2000,79(4),250-260","journal-title":"Medicine (Baltimore)"},{"key":"ref=44","first-page":"862","volume":"86","author":"Pagano L.","year":"2001","unstructured":"Pagano L.; Girmenia C.; Mele L.; Infections caused by filamentous fungi in patients with hematologic malignancies. A report of 391 cases by GIMEMA infection program. Haematologica 2001,86(8),862-870","journal-title":"Haematologica"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"4358","DOI":"10.1182\/blood-2002-05-1496","volume":"100","author":"Marr K.A.","year":"2002","unstructured":"Marr K.A.; Carter R.A.; Boeckh M.; Martin P.; Corey L.; Invasive aspergillosis in allogeneic stem cell transplant recipients: Changes in epidemiology and risk factors. Blood 2002,100(13),4358-4366","journal-title":"Blood"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1182\/blood-2003-02-0456","volume":"102","author":"Fukuda T.","year":"2003","unstructured":"Fukuda T.; Boeckh M.; Carter R.A.; Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning. Blood 2003,102(3),827-833","journal-title":"Blood"},{"key":"ref=47","first-page":"1068","volume":"91","author":"Pagano L.","year":"2006","unstructured":"Pagano L.; Caira M.; Candoni A.; The epidemiology of fungal infections in patients with hematologic malignancies: The SEIFEM-2004 study. Haematologica 2006,91(8),1068-1075","journal-title":"Haematologica"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1086\/595846","volume":"48","author":"Neofytos D.","year":"2009","unstructured":"Neofytos D.; Horn D.; Anaissie E.; Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of multicenter Prospective Antifungal Therapy (PATH) alliance registry. Clin Infect Dis 2009,48(3),265-273","journal-title":"Clin Infect Dis"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"e12898","DOI":"10.1111\/tid.12898","volume":"20","author":"Neofytos D.","year":"2018","unstructured":"Neofytos D.; Chatzis O.; Nasioudis D.; Epidemiology, risk factors and outcomes of invasive aspergillosis in solid organ transplant recipients in the swiss transplant cohort study. Transpl Infect Dis 2018,20(4),e12898","journal-title":"Transpl Infect Dis"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1086\/651262","volume":"50","author":"Pappas P.G.","year":"2010","unstructured":"Pappas P.G.; Alexander B.D.; Andes D.R.; Invasive fungal infections among organ transplant recipients: results of the transplant-associated infection surveillance network (TRANSNET). Clin Infect Dis 2010,50(8),1101-1111","journal-title":"Clin Infect Dis"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.diagmicrobio.2012.06.012","volume":"73","author":"Azie N.","year":"2012","unstructured":"Azie N.; Neofytos D.; Pfaller M.; Meier-Kriesche H-U.; Quan S-P.; Horn D.; The PATH (Prospective Antifungal Therapy) Alliance\u00ae registry and invasive fungal infections: Update 2012. Diagn Microbiol Infect Dis 2012,73(4),293-300","journal-title":"Diagn Microbiol Infect Dis"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"e12981","DOI":"10.1111\/tid.12981","volume":"20","author":"Kuster S.","year":"2018","unstructured":"Kuster S.; Stampf S.; Gerber B.; Incidence and outcome of invasive fungal diseases after allogeneic hematopoietic stem cell transplantation: A Swiss transplant cohort study. Transpl Infect Dis 2018,20(6),e12981","journal-title":"Transpl Infect Dis"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1186\/s12879-015-1329-6","volume":"15","author":"Harrison N.","year":"2015","unstructured":"Harrison N.; Mitterbauer M.; Tobudic S.; Incidence and characteristics of invasive fungal diseases in allogeneic hematopoietic stem cell transplant recipients: A retrospective cohort study. BMC Infect Dis 2015,15(1),584","journal-title":"BMC Infect Dis"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1111\/j.1749-6632.2012.06829.x","volume":"1272","author":"Herbrecht R.","year":"2012","unstructured":"Herbrecht R.; Bories P.; Moulin J.C.; Ledoux M.P.; Letscher-Bru V.; Risk stratification for invasive aspergillosis in immunocompromised patients. Ann N Y Acad Sci 2012,1272(1),23-30","journal-title":"Ann N Y Acad Sci"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1111\/myc.12382","volume":"58","author":"Beardsley J.","year":"2015","unstructured":"Beardsley J.; Denning D.W.; Chau N.V.; Yen N.T.B.; Crump J.A.; Day J.N.; Estimating the burden of fungal disease in Vietnam. Mycoses 2015,58(S5),101-106","journal-title":"Mycoses"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1111\/myc.12394","volume":"58","author":"Denning D.W.","year":"2015","unstructured":"Denning D.W.; Gugnani H.C.; Burden of serious fungal infections in Trinidad and Tobago. Mycoses 2015,58(Suppl. 5),80-84","journal-title":"Mycoses"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1182\/blood-2017-11-818286","volume":"131","author":"Ghez D.","year":"2018","unstructured":"Ghez D.; Calleja A.; Protin C.; Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib. Blood 2018,131(17),1955-1959","journal-title":"Blood"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1093\/cid\/cix687","volume":"66","author":"Chamilos G.","year":"2018","unstructured":"Chamilos G.; Lionakis M.S.; Kontoyiannis D.P.; Call for action: Invasive fungal infections associated with ibrutinib and other small molecule kinase inhibitors targeting immune signaling pathways. Clin Infect Dis 2018,66(1),140-148","journal-title":"Clin Infect Dis"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1309\/UJRV9DLC11RM3G8R","volume":"127","author":"Stergiopoulou T.","year":"2007","unstructured":"Stergiopoulou T.; Meletiadis J.; Roilides E.; Host-dependent patterns of tissue injury in invasive pulmonary aspergillosis. Am J Clin Pathol 2007,127(3),349-355","journal-title":"Am J Clin Pathol"},{"key":"ref=60","doi-asserted-by":"crossref","first-page":"e3606","DOI":"10.1093\/cid\/ciaa1065","volume":"73","author":"Bartoletti M.","year":"2021","unstructured":"Bartoletti M.; Pascale R.; Cricca M.; Epidemiology of invasive pulmonary aspergillosis among COVID-19 intubated patients: A prospective study. Clin Infect Dis 2021,73(11),e3606-e3614","journal-title":"Clin Infect Dis"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"e1634","DOI":"10.2139\/ssrn.3644400","volume":"73","author":"White L.","year":"2021","unstructured":"White L.; Dhillon R.; Cordey A.; A national strategy to diagnose COVID-19 associated invasive fungal disease in the ICU. Clin Infect Dis 2021,73(7),e1634-e1644","journal-title":"Clin Infect Dis"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/S2213-2600(18)30274-1","volume":"6","author":"Schauwvlieghe A.F.A.D.","year":"2018","unstructured":"Schauwvlieghe A.F.A.D.; Rijnders B.J.A.; Philips N.; Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: A retrospective cohort study. Lancet Respir Med 2018,6(10),782-792","journal-title":"Lancet Respir Med"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.jointm.2021.07.001","volume":"1","author":"Dimopoulos G.","year":"2021","unstructured":"Dimopoulos G.; Almyroudi M-P.; Myrianthefs P.; Rello J.; COVID-19-associated pulmonary aspergillosis (CAPA). J Intensive Med 2021,1(2),71-80","journal-title":"J Intensive Med"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1164\/rccm.202004-1038LE","volume":"202","author":"van Arkel A.L.E.","year":"2020","unstructured":"van Arkel A.L.E.; Rijpstra T.A.; Belderbos H.N.A.; van Wijngaarden P.; Verweij P.E.; Bentvelsen R.G.; COVID-19\u2013associated pulmonary aspergillosis. Am J Respir Crit Care Med 2020,202(1),132-135","journal-title":"Am J Respir Crit Care Med"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s13613-020-00686-4","volume":"10","author":"Rutsaert L","year":"2020","unstructured":"Rutsaert L; Steinfort N, Vna; COVID-19-associated invasive pulmonary aspergillosis. Ann Intensive Care 2020,10(1),71","journal-title":"Ann Intensive Care"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"e02136","DOI":"10.1128\/JCM.02136-20","volume":"59","author":"Borman A.M.","year":"2020","unstructured":"Borman A.M.; Palmer M.D.; Fraser M.; COVID-19-associated invasive aspergillosis: Data from the UK National Mycology Reference Laboratory. J Clin Microbiol 2020,59(1),e02136-e20","journal-title":"J Clin Microbiol"},{"key":"ref=67","unstructured":"Food and Drug AdministrationAvailable from:  (Accessed on February 12, 2022)."},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"D1388","DOI":"10.1093\/nar\/gkaa971","volume":"49","author":"Kim S.","year":"2021","unstructured":"Kim S.; Chen J.; Cheng T.; PubChem in 2021: New data content and improved web interfaces. Nucleic Acids Res 2021,49(D1),D1388-D1395","journal-title":"Nucleic Acids Res"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s40265-016-0538-7","volume":"76","author":"Stone N.R.H.","year":"2016","unstructured":"Stone N.R.H.; Bicanic T.; Salim R.; Hope W.; Liposomal amphotericin B (AmBisome\u00ae): A review of the pharmacokinetics, pharmacodynamics, clinical experience and future directions. Drugs 2016,76(4),485-500","journal-title":"Drugs"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"S260","DOI":"10.1093\/cid\/ciz076","volume":"68","author":"Groll A.H.","year":"2019","unstructured":"Groll A.H.; Rijnders B.J.A.; Walsh T.J.; Adler-Moore J.; Lewis R.E.; Br\u00fcggemann R.J.M.; Clinical pharmacokinetics, pharmacodynamics, safety and efficacy of liposomal amphotericin B. Clin Infect Dis 2019,68(Suppl. 4),S260-S274","journal-title":"Clin Infect Dis"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1128\/AAC.46.3.834-840.2002","volume":"46","author":"Bekersky I.","year":"2002","unstructured":"Bekersky I.; Fielding R.M.; Dressler D.E.; Lee J.W.; Buell D.N.; Walsh T.J.; Plasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate. Antimicrob Agents Chemother 2002,46(3),834-840","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1007\/s40265-013-0069-4","volume":"73","author":"Hamill R.J.","year":"2013","unstructured":"Hamill R.J.; Amphotericin B formulations: A comparative review of efficacy and toxicity. Drugs 2013,73(9),919-934","journal-title":"Drugs"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1093\/jac\/42.4.497","volume":"42","author":"Lass-Fl\u00f6rl C.","year":"1998","unstructured":"Lass-Fl\u00f6rl C.; Kofler G.; Kropshofer G.; In-vitro testing of susceptibility to amphotericin B is a reliable predictor of clinical outcome in invasive aspergillosis. J Antimicrob Chemother 1998,42(4),497-502","journal-title":"J Antimicrob Chemother"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1086\/515033","volume":"27","author":"Ellis M.","year":"1998","unstructured":"Ellis M.; Spence D.; de Pauw B.; An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis. Clin Infect Dis 1998,27(6),1406-1412","journal-title":"Clin Infect Dis"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1086\/514341","volume":"44","author":"Cornely O.A.","year":"2007","unstructured":"Cornely O.A.; Maertens J.; Bresnik M.; Liposomal amphotericin B as initial therapy for invasive mold infection: A randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis 2007,44(10),1289-1297","journal-title":"Clin Infect Dis"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1111\/j.1439-0507.2007.01362.x","volume":"50","author":"Cordonnier C.","year":"2007","unstructured":"Cordonnier C.; Bresnik M.; Ebrahimi R.; Liposomal amphotericin B (AmBisome) efficacy in confirmed invasive aspergillosis and other filamentous fungal infections in immunocompromised hosts: A pooled analysis. Mycoses 2007,50(3),205-209","journal-title":"Mycoses"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1111\/myc.12727","volume":"61","author":"Hoenigl M.","year":"2018","unstructured":"Hoenigl M.; Prattes J.; Neumeister P.; W\u00f6lfler A.; Krause R.; Real-world challenges and unmet needs in the diagnosis and treatment of suspected invasive pulmonary aspergillosis in patients with haematological diseases: An illustrative case study. Mycoses 2018,61(3),201-205","journal-title":"Mycoses"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1111\/myc.12759","volume":"61","author":"Reichert-Lima F.","year":"2018","unstructured":"Reichert-Lima F.; Lyra L.; Pontes L.; Surveillance for azoles resistance in Aspergillus spp. highlights a high number of amphotericin B-resistant isolates. Mycoses 2018,61(6),360-365","journal-title":"Mycoses"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"439","DOI":"10.3389\/fmicb.2012.00439","volume":"3","author":"Alcazar-Fuoli L.","year":"2013","unstructured":"Alcazar-Fuoli L.; Mellado E.; Ergosterol biosynthesis in Aspergillus fumigatus: Its relevance as an antifungal target and role in antifungal drug resistance. Front Microbiol 2013,3,439","journal-title":"Front Microbiol"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"92","DOI":"10.3389\/fmicb.2017.00092","volume":"8","author":"Dhingra S.","year":"2017","unstructured":"Dhingra S.; Cramer R.A.; Regulation of sterol biosynthesis in the human fungal pathogen Aspergillus fumigatus: Opportunities for therapeutic development. Front Microbiol 2017,8,92","journal-title":"Front Microbiol"},{"key":"ref=81","year":"2022","unstructured":"Food and Drug AdministrationAvailable from:  (Accessed on February 12, 2022).2022"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.2460\/ajvr.2005.66.1694","volume":"66","author":"Davis J.L.","year":"2005","unstructured":"Davis J.L.; Salmon J.H.; Papich M.G.; Pharmacokinetics and tissue distribution of itraconazole after oral and intravenous administration to horses. Am J Vet Res 2005,66(10),1694-1701","journal-title":"Am J Vet Res"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1126\/science.aap7999","volume":"360","author":"Fisher M.C.","year":"2018","unstructured":"Fisher M.C.; Hawkins N.J.; Sanglard D.; Gurr S.J.; Worldwide emergence of resistance to antifungal drugs challenges human health and food security. Science 2018,360(6390),739-742","journal-title":"Science"},{"key":"ref=84","year":"2022","unstructured":"Food and Drug AdministrationAvailable from:  (Accessed on February 12, 2022).2022"},{"key":"ref=85","year":"2022","unstructured":"Food and Drug AdministrationAvailable from:  (Accessed on February 12, 2022).2022"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"3262","DOI":"10.1128\/AAC.00251-13","volume":"57","author":"Hoenigl M.","year":"2013","unstructured":"Hoenigl M.; Duettmann W.; Raggam R.B.; Potential factors for inadequate voriconazole plasma concentrations in intensive care unit patients and patients with hematological malignancies. Antimicrob Agents Chemother 2013,57(7),3262-3267","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1056\/NEJMoa020191","volume":"347","author":"Herbrecht R.","year":"2002","unstructured":"Herbrecht R.; Denning D.W.; Patterson T.F.; Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002,347(6),408-415","journal-title":"N Engl J Med"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.2147\/DDDT.S145545","volume":"12","author":"Jenks J.D.","year":"2018","unstructured":"Jenks J.D.; Salzer H.J.F.; Prattes J.; Krause R.; Buchheidt D.; Hoenigl M.; Spotlight on isavuconazole in the treatment of invasive aspergillosis and mucormycosis: Design, development, and place in therapy. Drug Des Devel Ther 2018,12,1033-1044","journal-title":"Drug Des Devel Ther"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1111\/myc.12778","volume":"61","author":"Cornely O.A.","year":"2018","unstructured":"Cornely O.A.; Mullane K.M.; Ostrosky-Zeichner L.; Isavuconazole for treatment of rare invasive fungal diseases. Mycoses 2018,61(8),518-533","journal-title":"Mycoses"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1111\/myc.12777","volume":"61","author":"Marty F.M.","year":"2018","unstructured":"Marty F.M.; Cornely O.A.; Mullane K.M.; Isavuconazole for treatment of invasive fungal diseases caused by more than one fungal species. Mycoses 2018,61(7),485-497","journal-title":"Mycoses"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1111\/myc.12769","volume":"61","author":"Perfect J.R.","year":"2018","unstructured":"Perfect J.R.; Cornely O.A.; Heep M.; Isavuconazole treatment for rare fungal diseases and for invasive aspergillosis in patients with renal impairment: Challenges and lessons of the VITAL trial. Mycoses 2018,61(7),420-429","journal-title":"Mycoses"},{"key":"ref=92","year":"2022","unstructured":"Food and Drug AdministrationAvailable from:  (Accessed on February 12, 2022).2022"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","volume":"387","author":"Maertens J.A.","year":"2016","unstructured":"Maertens J.A.; Raad I.I.; Marr K.A.; Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): A phase 3, randomised-controlled, non-inferiority trial. Lancet 2016,387(10020),760-769","journal-title":"Lancet"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1097\/TP.0b013e3181837585","volume":"86","author":"Alexander B.D.","year":"2008","unstructured":"Alexander B.D.; Perfect J.R.; Daly J.S.; Posaconazole as salvage therapy in patients with invasive fungal infections after solid organ transplant. Transplantation 2008,86(6),791-796","journal-title":"Transplantation"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1086\/508774","volume":"44","author":"Walsh T.J.","year":"2007","unstructured":"Walsh T.J.; Raad I.; Patterson T.F.; Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: An externally controlled trial. Clin Infect Dis 2007,44(1),2-12","journal-title":"Clin Infect Dis"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1038\/sj.leu.2405065","volume":"22","author":"Raad I.I.","year":"2008","unstructured":"Raad I.I.; Hanna H.A.; Boktour M.; Novel antifungal agents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies: Posaconazole compared with high-dose lipid formulations of amphotericin B alone or in combination with caspofungin. Leukemia 2008,22(3),496-503","journal-title":"Leukemia"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2174\/1568005014606107","volume":"1","author":"Liu J.","year":"2001","unstructured":"Liu J.; Balasubramanian M.K.; 1,3-beta-Glucan synthase: A useful target for antifungal drugs. Curr Drug Targets Infect Disord 2001,1(2),159-169","journal-title":"Curr Drug Targets Infect Disord"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"e00710","DOI":"10.1128\/AAC.00710-17","volume":"61","author":"Moreno-Vel\u00e1squez S.D.","year":"2017","unstructured":"Moreno-Vel\u00e1squez S.D.; Seidel C.; Juvvadi P.R.; Steinbach W.J.; Read N.D.; Caspofungin-mediated growth inhibition and paradoxical growth in Aspergillus fumigatus involve fungicidal hyphal tip lysis coupled with regenerative intrahyphal growth and dynamic changes in \u03b2-1, 3-glucan synthase localization. Antimicrob Agents Chemother 2017,61(10),e00710-e00717","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3390\/jof4010005","volume":"4","author":"Wagener J.","year":"2017","unstructured":"Wagener J.; Loiko V.; Recent insights into the paradoxical effect of echinocandins. J Fungi (Basel) 2017,4(1),5","journal-title":"J Fungi (Basel)"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"e01690","DOI":"10.1128\/AAC.01690-16","volume":"61","author":"Loiko V.","year":"2017","unstructured":"Loiko V.; Wagener J.; The paradoxical effect of echinocandins in Aspergillus fumigatus relies on recovery of the \u03b2-1, 3-glucan synthase Fks1. Antimicrob Agents Chemother 2017,61(2),e01690-e16","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.jgar.2021.03.011","volume":"25","author":"Li F.","year":"2021","unstructured":"Li F.; Zhou M.; Jiao Z.; Zou Z.; Yu E.; He Z.; Caspofungin pharmacokinetics and probability of target attainment in ICU patients in China. J Glob Antimicrob Resist 2021,25,238-263","journal-title":"J Glob Antimicrob Resist"},{"key":"ref=102","year":"2022","unstructured":"Food and Drug AdministrationAvailable from:  (Accessed on February 12, 2022).2022"},{"key":"ref=103","year":"2022","unstructured":"Food and Drug AdministrationAvailable from:  (Accessed on February 12, 2022).2022"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1038\/bmt.2009.334","volume":"45","author":"Herbrecht R.","year":"2010","unstructured":"Herbrecht R.; Maertens J.; Baila L.; Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: An European organisation for research and treatment of cancer study. Bone Marrow Transplant 2010,45(7),1227-1233","journal-title":"Bone Marrow Transplant"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1093\/jac\/dkp355","volume":"64","author":"Viscoli C.","year":"2009","unstructured":"Viscoli C.; Herbrecht R.; Akan H.; An EORTC Phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients. J Antimicrob Chemother 2009,64(6),1274-1281","journal-title":"J Antimicrob Chemother"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1007\/s10096-010-1013-0","volume":"29","author":"Hiemenz J.W.","year":"2010","unstructured":"Hiemenz J.W.; Raad I.I.; Maertens J.A.; Efficacy of caspofungin as salvage therapy for invasive aspergillosis compared to standard therapy in a historical cohort. Eur J Clin Microbiol Infect Dis 2010,29(11),1387-1394","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/2047-783X-16-4-159","volume":"16","author":"Kofla G.","year":"2011","unstructured":"Kofla G.; Ruhnke M.; Pharmacology and metabolism of anidulafungin, caspofungin and micafungin in the treatment of invasive candidosis: Review of the literature. Eur J Med Res 2011,16(4),159-166","journal-title":"Eur J Med Res"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"81","DOI":"10.7326\/M13-2508","volume":"162","author":"Marr K.A.","year":"2015","unstructured":"Marr K.A.; Schlamm H.T.; Herbrecht R.; Combination antifungal therapy for invasive aspergillosis: A randomized trial. Ann Intern Med 2015,162(2),81-89","journal-title":"Ann Intern Med"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.jinf.2006.03.003","volume":"53","author":"Denning D.W.","year":"2006","unstructured":"Denning D.W.; Marr K.A.; Lau W.M.; Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J Infect 2006,53(5),337-349","journal-title":"J Infect"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"2888","DOI":"10.1002\/cncr.22348","volume":"107","author":"Maertens J.","year":"2006","unstructured":"Maertens J.; Glasmacher A.; Herbrecht R.; Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis. Cancer 2006,107(12),2888-2897","journal-title":"Cancer"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/ja.2016.89","volume":"70","author":"Krishnan B.R.","year":"2017","unstructured":"Krishnan B.R.; James K.D.; Polowy K.; CD101, a novel echinocandin with exceptional stability properties and enhanced aqueous solubility. J Antibiot (Tokyo) 2017,70(2),130-135","journal-title":"J Antibiot (Tokyo)"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"e00758","DOI":"10.1128\/AAC.00758-17","volume":"61","author":"Lakota E.A.","year":"2017","unstructured":"Lakota E.A.; Bader J.C.; Ong V.; Pharmacological basis of CD101 efficacy: Exposure shape matters. Antimicrob Agents Chemother 2017,61(11),e00758-e17","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"2868","DOI":"10.1093\/jac\/dkw214","volume":"71","author":"Pfaller M.A.","year":"2016","unstructured":"Pfaller M.A.; Messer S.A.; Rhomberg P.R.; Jones R.N.; Castanheira M.; Activity of a long-acting echinocandin, CD101, determined using CLSI and EUCAST reference methods, against Candida and Aspergillus spp., including echinocandin- and azole-resistant isolates. J Antimicrob Chemother 2016,71(10),2868-2873","journal-title":"J Antimicrob Chemother"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"e01627","DOI":"10.1128\/AAC.01627-16","volume":"61","author":"Sandison T.","year":"2017","unstructured":"Sandison T.; Ong V.; Lee J.; Thye D.; Safety and pharmacokinetics of CD101 IV, a novel echinocandin, in healthy adults. Antimicrob Agents Chemother 2017,61(2),e01627-e16","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"6100","DOI":"10.1128\/AAC.00620-16","volume":"60","author":"Locke J.B.","year":"2016","unstructured":"Locke J.B.; Almaguer A.L.; Zuill D.E.; Bartizal K.; Characterization of in vitro resistance development to the novel echinocandin CD101 in Candida species. Antimicrob Agents Chemother 2016,60(10),6100-6107","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"5099","DOI":"10.1128\/AAC.00432-11","volume":"55","author":"Walker S.S.","year":"2011","unstructured":"Walker S.S.; Xu Y.; Triantafyllou I.; Discovery of a novel class of orally active antifungal \u03b2-1,3-D-glucan synthase inhibitors. Antimicrob Agents Chemother 2011,55(11),5099-5106","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"e0084221","DOI":"10.1128\/AAC.00842-21","volume":"65","author":"Rubino C.M.","year":"2021","unstructured":"Rubino C.M.; Flanagan S.; Population pharmacokinetics of rezafungin in patients with fungal infections. Antimicrob Agents Chemother 2021,65(11),e0084221","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.jgar.2018.02.013","volume":"14","author":"Sofjan A.K.","year":"2018","unstructured":"Sofjan A.K.; Mitchell A.; Shah D.N.; Rezafungin (CD101), a next-generation echinocandin: A systematic literature review and assessment of possible place in therapy. J Glob Antimicrob Resist 2018,14,58-64","journal-title":"J Glob Antimicrob Resist"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"e0139021","DOI":"10.1128\/AAC.01390-21","volume":"66","author":"Ong V.","year":"2022","unstructured":"Ong V.; Wills S.; Watson D.; Sandison T.; Flanagan S.; Metabolism, excretion, and mass balance of [14c]-rezafungin in animals and humans. Antimicrob Agents Chemother 2022,66(1),e0139021","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"S203","DOI":"10.1093\/ofid\/ofaa439.457","author":"Pappas P.","year":"2020","unstructured":"Pappas P.; Kullberg B.J.; Vazquez J.A.;  In: Open Forum Infectious Diseases 2020,S203-S204","journal-title":"In: Open Forum Infectious Diseases"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"732223","DOI":"10.3389\/fcimb.2021.732223","volume":"11","author":"McCarty T.P.","year":"2021","unstructured":"McCarty T.P.; Pappas P.G.; Antifungal pipeline. Front Cell Infect Microbiol 2021,11,732223","journal-title":"Front Cell Infect Microbiol"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1093\/jac\/dky280","volume":"73","author":"Wiederhold N.P.","year":"2018","unstructured":"Wiederhold N.P.; Locke J.B.; Daruwala P.; Bartizal K.; Rezafungin (CD101) demonstrates potent in vitro activity against Aspergillus, including azole-resistant Aspergillus fumigatus isolates and cryptic species. J Antimicrob Chemother 2018,73(11),3063-3067","journal-title":"J Antimicrob Chemother"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"6872","DOI":"10.1128\/AAC.00701-16","volume":"60","author":"Ong V.","year":"2016","unstructured":"Ong V.; Hough G.; Schlosser M.; Preclinical evaluation of the stability, safety, and efficacy of CD101, a novel echinocandin. Antimicrob Agents Chemother 2016,60(11),6872-6879","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"4543","DOI":"10.1128\/AAC.00366-11","volume":"55","author":"Hata K.","year":"2011","unstructured":"Hata K.; Horii T.; Miyazaki M.; Efficacy of oral E1210, a new broad-spectrum antifungal with a novel mechanism of action, in murine models of candidiasis, aspergillosis, and fusariosis. Antimicrob Agents Chemother 2011,55(10),4543-4551","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"e02068","DOI":"10.1128\/AAC.02068-16","volume":"61","author":"Wring S.A.","year":"2017","unstructured":"Wring S.A.; Randolph R.; Park S.; Preclinical pharmacokinetics and pharmacodynamic target of SCY-078, a first-in-class orally active antifungal glucan synthesis inhibitor, in murine models of disseminated candidiasis. Antimicrob Agents Chemother 2017,61(4),e02068-e16","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"e01102","DOI":"10.1128\/AAC.01102-17","volume":"61","author":"Schell W.A.","year":"2017","unstructured":"Schell W.A.; Jones A.M.; Borroto-Esoda K.; Alexander B.D.; Antifungal activity of SCY-078 and standard antifungal agents against 178 clinical isolates of resistant and susceptible Candida species. Antimicrob Agents Chemother 2017,61(11),e01102-e01117","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"e02268","DOI":"10.1128\/AAC.02268-19","volume":"64","author":"Lee A.","year":"2020","unstructured":"Lee A.; Prideaux B.; Zimmerman M.; Penetration of Ibrexafungerp (formerly SCY-078) at the site of infection in an Intra-abdominal candidiasis mouse model. Antimicrob Agents Chemother 2020,64(3),e02268-e19","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"S328","DOI":"10.1093\/mmy\/myz012","volume":"57","author":"Van Daele R.","year":"2019","unstructured":"Van Daele R.; Spriet I.; Wauters J.; Antifungal drugs: What brings the future? Med Mycol 2019,57(Suppl. 3),S328-S343","journal-title":"Med Mycol"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1002\/jcph.1146","volume":"58","author":"Wring S.","year":"2018","unstructured":"Wring S.; Murphy G.; Atiee G.; Lack of impact by SCY-078, a first-in-class oral fungicidal glucan synthase inhibitor, on the pharmacokinetics of rosiglitazone, a substrate for CYP450 2C8, supports the low risk for clinically relevant metabolic drug-drug interactions. J Clin Pharmacol 2018,58(10),1305-1313","journal-title":"J Clin Pharmacol"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1002\/cpdd.588","volume":"8","author":"Wring S.","year":"2019","unstructured":"Wring S.; Murphy G.; Atiee G.; Clinical pharmacokinetics and drug-drug interaction potential for coadministered SCY-078, an oral fungicidal glucan synthase inhibitor, and tacrolimus. Clin Pharmacol Drug Dev 2019,8(1),60-69","journal-title":"Clin Pharmacol Drug Dev"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1080\/13543784.2020.1791820","volume":"29","author":"Azie N.","year":"2020","unstructured":"Azie N.; Angulo D.; Dehn B.; Sobel J.D.; Oral Ibrexafungerp: An investigational agent for the treatment of vulvovaginal candidiasis. Expert Opin Investig Drugs 2020,29(9),893-900","journal-title":"Expert Opin Investig Drugs"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1093\/mmy\/myz083","volume":"58","author":"Davis M.R.","year":"2020","unstructured":"Davis M.R.; Donnelley M.A.; Thompson G.R.; Ibrexafungerp: A novel oral glucan synthase inhibitor. Med Mycol 2020,58(5),579-592","journal-title":"Med Mycol"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1086\/319760","volume":"32","author":"Allos B.M.","year":"2001","unstructured":"Allos B.M.; Campylobacter jejuni Infections: Update on emerging issues and trends. Clin Infect Dis 2001,32(8),1201-1206","journal-title":"Clin Infect Dis"},{"key":"ref=134","year":"2022","unstructured":"Food And Drug AdministrationAvailable from:  (Accessed on February 12, 2022).2022"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1128\/AAC.01588-12","volume":"57","author":"Pfaller M.A.","year":"2013","unstructured":"Pfaller M.A.; Messer S.A.; Motyl M.R.; Jones R.N.; Castanheira M.; In vitro activity of a new oral glucan synthase inhibitor (MK-3118) tested against Aspergillus spp. by CLSI and EUCAST broth microdilution methods. Antimicrob Agents Chemother 2013,57(2),1065-1068","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1128\/AAC.02145-13","volume":"58","author":"Jim\u00e9nez-Ortigosa C.","year":"2014","unstructured":"Jim\u00e9nez-Ortigosa C.; Paderu P.; Motyl M.R.; Perlin D.S.; Enfumafungin derivative MK-3118 shows increased in vitro potency against clinical echinocandin-resistant Candida Species and Aspergillus species isolates. Antimicrob Agents Chemother 2014,58(2),1248-1251","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"4652","DOI":"10.1128\/AAC.00291-11","volume":"55","author":"Miyazaki M.","year":"2011","unstructured":"Miyazaki M.; Horii T.; Hata K.; In vitro activity of E1210, a novel antifungal, against clinically important yeasts and molds. Antimicrob Agents Chemother 2011,55(10),4652-4658","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"e02372","DOI":"10.1128\/AAC.02372-18","volume":"63","author":"Zhao M.","year":"2019","unstructured":"Zhao M.; Lepak A.J.; Marchillo K.; APX001 pharmacokinetic\/pharmacodynamic target determination against Aspergillus fumigatus in an in vivo model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother 2019,63(4),e02372-e18","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"e01795","DOI":"10.1128\/AAC.01795-20","volume":"65","author":"Petraitiene R.","year":"2021","unstructured":"Petraitiene R.; Petraitis V.; Maung B.B.W.; Efficacy and pharmacokinetics of fosmanogepix (APX001) in the treatment of candida endophthalmitis and hematogenous meningoencephalitis in nonneutropenic rabbits. Antimicrob Agents Chemother 2021,65(3),e01795-e20","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"e01735","DOI":"10.1128\/AAC.01735-19","volume":"64","author":"Alkhazraji S.","year":"2020","unstructured":"Alkhazraji S.; Gebremariam T.; Alqarihi A.; Fosmanogepix (APX001) is effective in the treatment of immunocompromised mice infected with invasive pulmonary scedosporiosis or disseminated fusariosis. Antimicrob Agents Chemother 2020,64(3),e01735-e19","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1128\/AAC.00731-11","volume":"56","author":"Watanabe N.A.","year":"2012","unstructured":"Watanabe N.A.; Miyazaki M.; Horii T.; Sagane K.; Tsukahara K.; Hata K.; E1210, a new broad-spectrum antifungal, suppresses Candida albicans hyphal growth through inhibition of glycosylphosphatidylinositol biosynthesis. Antimicrob Agents Chemother 2012,56(2),960-971","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"7121","DOI":"10.1128\/AAC.03707-14","volume":"58","author":"Warrilow A.G.S.","year":"2014","unstructured":"Warrilow A.G.S.; Hull C.M.; Parker J.E.; The clinical candidate VT-1161 is a highly potent inhibitor of Candida albicans CYP51 but fails to bind the human enzyme. Antimicrob Agents Chemother 2014,58(12),7121-7127","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"4530","DOI":"10.1128\/AAC.00349-16","volume":"60","author":"Warrilow A.G.S.","year":"2016","unstructured":"Warrilow A.G.S.; Parker J.E.; Price C.L.; The investigational drug VT-1129 is a highly potent inhibitor of Cryptococcus species CYP51 but only weakly inhibits the human enzyme. Antimicrob Agents Chemother 2016,60(8),4530-4538","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=144","doi-asserted-by":"publisher","first-page":"3455","DOI":"10.1016\/j.bmcl.2014.05.068","volume":"24","author":"Hoekstra W.J.","year":"2014","unstructured":"Hoekstra W.J.; Garvey E.P.; Moore W.R.; Rafferty S.W.; Yates C.M.; Schotzinger R.J.; Design and optimization of highly-selective fungal CYP51 inhibitors. Bioorg Med Chem Lett 2014,24(15),3455-3458","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=145","doi-asserted-by":"publisher","first-page":"e02258","DOI":"10.1128\/AAC.02258-17","volume":"62","author":"Wiederhold N.P.","year":"2018","unstructured":"Wiederhold N.P.; Shubitz L.F.; Najvar L.K.; The novel fungal Cyp51 inhibitor VT-1598 is efficacious in experimental models of central nervous system coccidioidomycosis caused by Coccidioides posadasii and Coccidioides immitis. Antimicrob Agents Chemother 2018,62(4),e02258-e17","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=146","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1093\/jac\/dkx410","volume":"73","author":"Wiederhold N.P.","year":"2018","unstructured":"Wiederhold N.P.; Patterson H.P.; Tran B.H.; Yates C.M.; Schotzinger R.J.; Garvey E.P.; Fungal-specific Cyp51 inhibitor VT-1598 demonstrates in vitro activity against Candida and Cryptococcus species, endemic fungi, including Coccidioides species, Aspergillus species and Rhizopus arrhizus. J Antimicrob Chemother 2018,73(2),404-408","journal-title":"J Antimicrob Chemother"},{"key":"ref=147","doi-asserted-by":"publisher","first-page":"2950","DOI":"10.1093\/jac\/dkz302","volume":"74","author":"Colley T.","year":"2019","unstructured":"Colley T.; Sharma C.; Alanio A.; Anti-fungal activity of a novel triazole, PC1244, against emerging azole-resistant Aspergillus fumigatus and other species of Aspergillus. J Antimicrob Chemother 2019,74(10),2950-2958","journal-title":"J Antimicrob Chemother"},{"key":"ref=148","doi-asserted-by":"publisher","first-page":"28","DOI":"10.3390\/jof6010028","volume":"6","author":"Gintjee T.J.","year":"2020","unstructured":"Gintjee T.J.; Donnelley M.A.; Thompson G.R.; Aspiring antifungals: Review of current antifungal pipeline developments. J Fungi (Basel) 2020,6(1),28","journal-title":"J Fungi (Basel)"},{"key":"ref=149","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1007\/s40265-017-0805-2","volume":"77","author":"Gonzalez-Lara M.F.","year":"2017","unstructured":"Gonzalez-Lara M.F.; Sifuentes-Osornio J.; Ostrosky-Zeichner L.; Drugs in clinical development for fungal infections. Drugs 2017,77(14),1505-1518","journal-title":"Drugs"},{"key":"ref=150","doi-asserted-by":"publisher","first-page":"2356","DOI":"10.1128\/AAC.44.9.2356-2360.2000","volume":"44","author":"Santangelo R.","year":"2000","unstructured":"Santangelo R.; Paderu P.; Delmas G.; Efficacy of oral cochleate-amphotericin B in a mouse model of systemic candidiasis. Antimicrob Agents Chemother 2000,44(9),2356-2360","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=151","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1128\/AAC.44.6.1463-1469.2000","volume":"44","author":"Zarif L.","year":"2000","unstructured":"Zarif L.; Graybill J.R.; Perlin D.; Najvar L.; Bocanegra R.; Mannino R.J.; Antifungal activity of amphotericin B cochleates against Candida albicans infection in a mouse model. Antimicrob Agents Chemother 2000,44(6),1463-1469","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=152","doi-asserted-by":"publisher","first-page":"2704","DOI":"10.1128\/AAC.46.8.2704-2707.2002","volume":"46","author":"Delmas G.","year":"2002","unstructured":"Delmas G.; Park S.; Chen Z.W.; Efficacy of orally delivered cochleates containing amphotericin B in a murine model of aspergillosis. Antimicrob Agents Chemother 2002,46(8),2704-2707","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=153","doi-asserted-by":"publisher","first-page":"99","DOI":"10.3390\/pharmaceutics11030099","volume":"11","author":"Cuddihy G.","year":"2019","unstructured":"Cuddihy G.; Wasan E.K.; Di Y.; Wasan K.M.; The development of oral amphotericin B to treat systemic fungal and parasitic infections: Has the myth been finally realized? Pharmaceutics 2019,11(3),99","journal-title":"Pharmaceutics"},{"key":"ref=154","doi-asserted-by":"publisher","first-page":"e01111","DOI":"10.1128\/AAC.01111-20","volume":"64","author":"Wasan K.M.","year":"2020","unstructured":"Wasan K.M.; Wasan E.K.; Hnik P.; Assessing the safety, tolerability, pharmacokinetics, and biodistribution of novel oral formulations of amphotericin B following single-and multiple-dose administration to beagle dogs. Antimicrob Agents Chemother 2020,64(11),e01111-e01120","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=155","doi-asserted-by":"publisher","first-page":"e00724","DOI":"10.1128\/mBio.00724-19","volume":"10","author":"Lu R.","year":"2019","unstructured":"Lu R.; Hollingsworth C.; Qiu J.; Efficacy of oral encochleated amphotericin B in a mouse model of cryptococcal meningoencephalitis. MBio 2019,10(3),e00724-e19","journal-title":"MBio"},{"key":"ref=156","doi-asserted-by":"publisher","first-page":"108","DOI":"10.2323\/jgam.61.108","volume":"61","author":"Wang X.H.","year":"2015","unstructured":"Wang X.H.; Guo X-J.; Li H-Y.; Gou P.; Characteristics of inositol phosphorylceramide synthase and effects of aureobasidin A on growth and pathogenicity of Botrytis cinerea. J Gen Appl Microbiol 2015,61(4),108-116","journal-title":"J Gen Appl Microbiol"},{"key":"ref=157","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/nrd.2017.46","volume":"16","author":"Perfect J.R.","year":"2017","unstructured":"Perfect J.R.; The antifungal pipeline: A reality check. Nat Rev Drug Discov 2017,16(9),603-616","journal-title":"Nat Rev Drug Discov"},{"key":"ref=158","doi-asserted-by":"publisher","first-page":"96","DOI":"10.3389\/fmicb.2015.00096","volume":"6","author":"Lamoth F.","year":"2015","unstructured":"Lamoth F.; Juvvadi P.R.; Steinbach W.J.; Histone deacetylase inhibition as an alternative strategy against invasive aspergillosis. Front Microbiol 2015,6,96","journal-title":"Front Microbiol"},{"key":"ref=159","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1038\/nm.2175","volume":"16","author":"Wurtele H.","year":"2010","unstructured":"Wurtele H.; Tsao S.; L\u00e9pine G.; Modulation of histone H3 lysine 56 acetylation as an antifungal therapeutic strategy. Nat Med 2010,16(7),774-780","journal-title":"Nat Med"},{"key":"ref=160","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1093\/jac\/dkq177","volume":"65","author":"Nishikawa H.","year":"2010","unstructured":"Nishikawa H.; Yamada E.; Shibata T.; Uptake of T-2307, a novel arylamidine, in Candida albicans. J Antimicrob Chemother 2010,65(8),1681-1687","journal-title":"J Antimicrob Chemother"},{"key":"ref=161","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1128\/AAC.01159-07","volume":"52","author":"Mitsuyama J.","year":"2008","unstructured":"Mitsuyama J.; Nomura N.; Hashimoto K.; In vitro and in vivo antifungal activities of T-2307, a novel arylamidine. Antimicrob Agents Chemother 2008,52(4),1318-1324","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=162","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1111\/j.1439-0507.2012.02225.x","volume":"56","author":"Tan H.W.","year":"2013","unstructured":"Tan H.W.; Tay S.T.; The inhibitory effects of aureobasidin A on Candida planktonic and biofilm cells. Mycoses 2013,56(2),150-156","journal-title":"Mycoses"},{"key":"ref=163","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.7164\/antibiotics.46.1414","volume":"46","author":"Takesako K.","year":"1993","unstructured":"Takesako K.; Kuroda H.; Inoue T.; Biological properties of aureobasidin A, a cyclic depsipeptide antifungal antibiotic. J Antibiot (Tokyo) 1993,46(9),1414-1420","journal-title":"J Antibiot (Tokyo)"},{"key":"ref=164","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1128\/AAC.44.3.651-653.2000","volume":"44","author":"Zhong W.","year":"2000","unstructured":"Zhong W.; Jeffries M.W.; Georgopapadakou N.H.; Inhibition of inositol phosphorylceramide synthase by aureobasidin A in Candida and Aspergillus species. Antimicrob Agents Chemother 2000,44(3),651-653","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=165","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.pharmthera.2018.10.008","volume":"195","author":"Nicola A.M.","year":"2019","unstructured":"Nicola A.M.; Albuquerque P.; Paes H.C.; Antifungal drugs: New insights in research","journal-title":"Pharmacol Ther"},{"key":"ref=166","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/ja.2016.106","volume":"70","author":"Nakamura I.","year":"2017","unstructured":"Nakamura I.; Kanasaki R.; Yoshikawa K.; Discovery of a new antifungal agent ASP2397 using a silkworm model of Aspergillus fumigatus infection. J Antibiot (Tokyo) 2017,70(1),41-44","journal-title":"J Antibiot (Tokyo)"},{"key":"ref=167","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1128\/AAC.02336-15","volume":"60","author":"Arendrup M.C.","year":"2015","unstructured":"Arendrup M.C.; Jensen R.H.; Cuenca-Estrella M.; In vitro activity of ASP2397 against Aspergillus isolates with or without acquired azole resistance mechanisms. Antimicrob Agents Chemother 2015,60(1),532-536","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=168","doi-asserted-by":"publisher","first-page":"3068","DOI":"10.1093\/jac\/dky329","volume":"73","author":"Lackner M.","year":"2018","unstructured":"Lackner M.; Birch M.; Naschberger V.; Dihydroorotate dehydrogenase inhibitor olorofim exhibits promising activity against all clinically relevant species within Aspergillus section Terrei. J Antimicrob Chemother 2018,73(11),3068-3073","journal-title":"J Antimicrob Chemother"},{"key":"ref=169","doi-asserted-by":"publisher","first-page":"e02689","DOI":"10.1128\/AAC.02689-18","volume":"63","author":"Nakamura I.","year":"2019","unstructured":"Nakamura I.; Ohsumi K.; Takeda S.; ASP2397 is a novel natural compound that exhibits rapid and potent fungicidal activity against Aspergillus species through a specific transporter. Antimicrob Agents Chemother 2019,63(10),e02689-e18","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=170","doi-asserted-by":"publisher","first-page":"e00969","DOI":"10.1128\/AAC.00969-19","volume":"63","author":"Mammen M.P.","year":"2019","unstructured":"Mammen M.P.; Armas D.; Hughes F.H.; First-in-human phase 1 study to assess safety, tolerability, and pharmacokinetics of a novel antifungal drug, VL-2397, in healthy adults. Antimicrob Agents Chemother 2019,63(11),e00969-e19","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=171","doi-asserted-by":"publisher","first-page":"e00163","DOI":"10.1128\/AAC.00163-19","volume":"63","author":"Kovanda L.L.","year":"2019","unstructured":"Kovanda L.L.; Sullivan S.M.; Smith L.R.; Desai A.V.; Bonate P.L.; Hope W.W.; Population pharmacokinetic modeling of VL-2397, a novel systemic antifungal agent: Analysis of a single-and multiple-ascending-dose study in healthy subjects. Antimicrob Agents Chemother 2019,63(6),e00163-e19","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=172","doi-asserted-by":"publisher","first-page":"12809","DOI":"10.1073\/pnas.1608304113","volume":"113","author":"Oliver J.D.","year":"2016","unstructured":"Oliver J.D.; Sibley G.E.M.; Beckmann N.; F901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase. Proc Natl Acad Sci USA 2016,113(45),12809-12814","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=173","doi-asserted-by":"publisher","first-page":"e01157","DOI":"10.1128\/mBio.01157-17","volume":"8","author":"Hope W.W.","year":"2017","unstructured":"Hope W.W.; McEntee L.; Livermore J.; Pharmacodynamics of the orotomides against Aspergillus fumigatus: New opportunities for treatment of multidrug-resistant fungal disease. MBio 2017,8(4),e01157-e17","journal-title":"MBio"},{"key":"ref=174","doi-asserted-by":"publisher","first-page":"e00231","DOI":"10.1128\/AAC.00231-18","volume":"62","author":"du Pr\u00e9 S.","year":"2018","unstructured":"du Pr\u00e9 S.; Beckmann N.; Almeida M.C.; Effect of the novel antifungal drug F901318 (olorofim) on growth and viability of Aspergillus fumigatus. Antimicrob Agents Chemother 2018,62(8),e00231-e18","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=175","doi-asserted-by":"publisher","first-page":"122","DOI":"10.3390\/jof6030122","volume":"6","author":"Wiederhold N.P.","year":"2020","unstructured":"Wiederhold N.P.; Review of the novel investigational antifungal olorofim. J Fungi (Basel) 2020,6(3),122","journal-title":"J Fungi (Basel)"},{"key":"ref=176","doi-asserted-by":"publisher","first-page":"2548","DOI":"10.1093\/jac\/dkx177","volume":"72","author":"Buil J.B.","year":"2017","unstructured":"Buil J.B.; Rijs A.J.M.M.; Meis J.F.; In vitro activity of the novel antifungal compound F901318 against difficult-to-treat Aspergillus isolates. J Antimicrob Chemother 2017,72(9),2548-2552","journal-title":"J Antimicrob Chemother"},{"key":"ref=177","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1093\/jac\/dkz078","volume":"74","author":"Rivero-Menendez O.","year":"2019","unstructured":"Rivero-Menendez O.; Cuenca-Estrella M.; Alastruey-Izquierdo A.; In vitro activity of olorofim (F901318) against clinical isolates of cryptic species of Aspergillus by EUCAST and CLSI methodologies. J Antimicrob Chemother 2019,74(6),1586-1590","journal-title":"J Antimicrob Chemother"},{"key":"ref=178","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1093\/infdis\/jix479","volume":"217","author":"Negri C.E.","year":"2018","unstructured":"Negri C.E.; Johnson A.; McEntee L.; Pharmacodynamics of the novel antifungal agent F901318 for acute sinopulmonary aspergillosis caused by Aspergillus flavus. J Infect Dis 2018,217(7),1118-1127","journal-title":"J Infect Dis"},{"key":"ref=179","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1021\/ml300173e","volume":"3","author":"Singh S.B.","year":"2012","unstructured":"Singh S.B.; Liu W.; Li X.; Antifungal spectrum, in vivo efficacy, and structure-activity relationship of ilicicolin h. ACS Med Chem Lett 2012,3(10),814-817","journal-title":"ACS Med Chem Lett"},{"key":"ref=180","doi-asserted-by":"publisher","first-page":"8708","DOI":"10.1074\/jbc.M311805200","volume":"279","author":"Gutierrez-Cirlos E.B.","year":"2004","unstructured":"Gutierrez-Cirlos E.B.; Merbitz-Zahradnik T.; Trumpower B.L.; Inhibition of the yeast cytochrome bc1 complex by ilicicolin H, a novel inhibitor that acts at the Qn site of the bc1 complex. J Biol Chem 2004,279(10),8708-8714","journal-title":"J Biol Chem"},{"key":"ref=181","doi-asserted-by":"publisher","first-page":"3018","DOI":"10.1016\/j.bmcl.2013.03.023","volume":"23","author":"Singh S.B.","year":"2013","unstructured":"Singh S.B.; Liu W.; Li X.; Structure-activity relationship of cytochrome bc1 reductase inhibitor broad spectrum antifungal ilicicolin H. Bioorg Med Chem Lett 2013,23(10),3018-3022","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=182","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.7164\/antibiotics.40.1249","volume":"40","author":"Kino T.","year":"1987","unstructured":"Kino T.; Hatanaka H.; Hashimoto M.; FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics. J Antibiot (Tokyo) 1987,40(9),1249-1255","journal-title":"J Antibiot (Tokyo)"},{"key":"ref=183","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1097\/00007890-199457120-00001","volume":"57","author":"High K.P.","year":"1994","unstructured":"High K.P.; The antimicrobial activities of cyclosporine, FK506, and rapamycin. Transplantation 1994,57(12),1689-1700","journal-title":"Transplantation"},{"key":"ref=184","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.fbr.2014.02.004","volume":"28","author":"Juvvadi P.R.","year":"2014","unstructured":"Juvvadi P.R.; Lamoth F.; Steinbach W.J.; Calcineurin as a multifunctional regulator: Unraveling novel functions in fungal stress responses, hyphal growth, drug resistance, and pathogenesis. Fungal Biol Rev 2014,28(2-3),56-69","journal-title":"Fungal Biol Rev"},{"key":"ref=185","doi-asserted-by":"publisher","first-page":"7097","DOI":"10.1128\/AAC.01510-15","volume":"59","author":"Gao L.","year":"2015","unstructured":"Gao L.; Sun Y.; In vitro interactions of antifungal agents and tacrolimus against Aspergillus biofilms. Antimicrob Agents Chemother 2015,59(11),7097-7099","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=186","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1128\/AAC.48.5.1664-1669.2004","volume":"48","author":"Steinbach W.J.","year":"2004","unstructured":"Steinbach W.J.; Schell W.A.; Blankenship J.R.; Onyewu C.; Heitman J.; Perfect J.R.; In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus. Antimicrob Agents Chemother 2004,48(5),1664-1669","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=187","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1093\/infdis\/175.1.222","volume":"175","author":"High K.P.","year":"1997","unstructured":"High K.P.; Washburn R.G.; Invasive aspergillosis in mice immunosuppressed with cyclosporin A, tacrolimus (FK506), or sirolimus (rapamycin). J Infect Dis 1997,175(1),222-225","journal-title":"J Infect Dis"},{"key":"ref=188","doi-asserted-by":"publisher","first-page":"e00831","DOI":"10.1128\/mBio.00831-16","volume":"7","author":"Bauer I.","year":"2016","unstructured":"Bauer I.; Varadarajan D.; Pidroni A.; A class 1 histone deacetylase with potential as an antifungal target. MBio 2016,7(6),e00831-e16","journal-title":"MBio"},{"key":"ref=189","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1093\/jac\/dku549","volume":"70","author":"Lamoth F.","year":"2015","unstructured":"Lamoth F.; Alexander B.D.; Juvvadi P.R.; Steinbach W.J.; Antifungal activity of compounds targeting the Hsp90-calcineurin pathway against various mould species. J Antimicrob Chemother 2015,70(5),1408-1411","journal-title":"J Antimicrob Chemother"},{"key":"ref=190","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1128\/AAC.02286-13","volume":"58","author":"Lamoth F.","year":"2014","unstructured":"Lamoth F.; Juvvadi P.R.; Soderblom E.J.; Moseley M.A.; Asfaw Y.G.; Steinbach W.J.; Identification of a key lysine residue in heat shock protein 90 required for azole and echinocandin resistance in Aspergillus fumigatus. Antimicrob Agents Chemother 2014,58(4),1889-1896","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=191","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1379\/1466-1268(2001)006<0105:GTPOAC>2.0.CO;2","volume":"6","author":"Ochel H-J.","year":"2001","unstructured":"Ochel H-J.; Eichhorn K.; Gademann G.; Geldanamycin: The prototype of a class of antitumor drugs targeting the heat shock protein 90 family of molecular chaperones. Cell Stress Chaperones 2001,6(2),105-112","journal-title":"Cell Stress Chaperones"},{"key":"ref=192","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1128\/AAC.01857-12","volume":"57","author":"Lamoth F.","year":"2013","unstructured":"Lamoth F.; Juvvadi P.R.; Gehrke C.; Steinbach W.J.; In vitro activity of calcineurin and heat shock protein 90 Inhibitors against Aspergillus fumigatus azole- and echinocandin-resistant strains. Antimicrob Agents Chemother 2013,57(2),1035-1039","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=193","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1093\/jac\/dkg090","volume":"51","author":"Kontoyiannis D.P.","year":"2003","unstructured":"Kontoyiannis D.P.; Lewis R.E.; Osherov N.; Albert N.D.; May G.S.; Combination of caspofungin with inhibitors of the calcineurin pathway attenuates growth in vitro in Aspergillus species. J Antimicrob Chemother 2003,51(2),313-316","journal-title":"J Antimicrob Chemother"},{"key":"ref=194","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.ijantimicag.2015.02.011","volume":"45","author":"Dalhoff A.A.H.","year":"2015","unstructured":"Dalhoff A.A.H.; Levy S.B.; Does use of the polyene natamycin as a food preservative jeopardise the clinical efficacy of amphotericin B? A word of concern. Int J Antimicrob Agents 2015,45(6),564-567","journal-title":"Int J Antimicrob Agents"},{"key":"ref=195","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3389\/fcell.2016.00057","volume":"4","author":"Ciesielski F.","year":"2016","unstructured":"Ciesielski F.; Griffin D.C.; Loraine J.; Rittig M.; Delves-Broughton J.; Bonev B.B.; Recognition of membrane sterols by polyene antifungals amphotericin B and natamycin, a 13C MAS NMR study. Front Cell Dev Biol 2016,4,57","journal-title":"Front Cell Dev Biol"},{"key":"ref=196","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ijfoodmicro.2016.08.006","volume":"238","author":"Streekstra H.","year":"2016","unstructured":"Streekstra H.; Verkennis A.E.E.; Jacobs R.; Dekker A.; Stark J.; Dijksterhuis J.; Fungal strains and the development of tolerance against natamycin. Int J Food Microbiol 2016,238,15-22","journal-title":"Int J Food Microbiol"},{"key":"ref=197","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1093\/mmy\/myx119","volume":"56","author":"Posch W.","year":"2018","unstructured":"Posch W.; Blatzer M.; Wilflingseder D.; Lass-Fl\u00f6rl C.; Aspergillus terreus: Novel lessons learned on amphotericin B resistance. Med Mycol 2018,56(Suppl. 1),73-82","journal-title":"Med Mycol"},{"key":"ref=198","doi-asserted-by":"publisher","first-page":"e02593","DOI":"10.1128\/AAC.02593-17","volume":"62","author":"Gsaller F.","year":"2018","unstructured":"Gsaller F.; Furukawa T.; Carr P.D.; Mechanistic basis of pH-dependent 5-flucytosine resistance in Aspergillus fumigatus. Antimicrob Agents Chemother 2018,62(6),e02593-e17","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=199","doi-asserted-by":"publisher","first-page":"e383","DOI":"10.1016\/S1473-3099(17)30316-X","volume":"17","author":"Perlin D.S.","year":"2017","unstructured":"Perlin D.S.; Rautemaa-Richardson R.; Alastruey-Izquierdo A.; The global problem of antifungal resistance: Prevalence, mechanisms, and management. Lancet Infect Dis 2017,17(12),e383-e392","journal-title":"Lancet Infect Dis"},{"key":"ref=200","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1093\/cid\/civ885","volume":"62","author":"Verweij P.E.","year":"2016","unstructured":"Verweij P.E.; Chowdhary A.; Melchers W.J.G.; Meis J.F.; Azole resistance in Aspergillus fumigatus: Can we retain the clinical use of mold-active antifungal azoles? Clin Infect Dis 2016,62(3),362-368","journal-title":"Clin Infect Dis"},{"key":"ref=201","doi-asserted-by":"publisher","first-page":"e251","DOI":"10.1016\/S1473-3099(16)30138-4","volume":"16","author":"Verweij P.E.","year":"2016","unstructured":"Verweij P.E.; Zhang J.; Debets A.J.M.; In-host adaptation and acquired triazole resistance in Aspergillus fumigatus: A dilemma for clinical management. Lancet Infect Dis 2016,16(11),e251-e260","journal-title":"Lancet Infect Dis"},{"key":"ref=202","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.medmal.2013.02.010","volume":"43","author":"Leli\u00e8vre L.","year":"2013","unstructured":"Leli\u00e8vre L.; Groh M.; Angebault C.; Maherault A-C.; Didier E.; Bougnoux M-E.; Azole resistant Aspergillus fumigatus: An emerging problem. Med Mal Infect 2013,43(4),139-145","journal-title":"Med Mal Infect"},{"key":"ref=203","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.3201\/eid1507.090043","volume":"15","author":"Howard S.J.","year":"2009","unstructured":"Howard S.J.; Cerar D.; Anderson M.J.; Frequency and evolution of Azole resistance in Aspergillus fumigatus associated with treatment failure. Emerg Infect Dis 2009,15(7),1068-1076","journal-title":"Emerg Infect Dis"},{"key":"ref=204","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1093\/jac\/44.4.553","volume":"44","author":"Dannaoui E.","year":"1999","unstructured":"Dannaoui E.; Persat F.; Monier M-F.; Borel E.; Piens M-A.; Picot S.; In-vitro susceptibility of Aspergillus spp. isolates to amphotericin B and itraconazole. J Antimicrob Chemother 1999,44(4),553-555","journal-title":"J Antimicrob Chemother"},{"key":"ref=205","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1093\/jac\/dkq450","volume":"66","author":"Alanio A.","year":"2011","unstructured":"Alanio A.; Sitterl\u00e9 E.; Liance M.; Low prevalence of resistance to azoles in Aspergillus fumigatus in a French cohort of patients treated for haematological malignancies. J Antimicrob Chemother 2011,66(2),371-374","journal-title":"J Antimicrob Chemother"},{"key":"ref=206","doi-asserted-by":"publisher","first-page":"4545","DOI":"10.1128\/AAC.00692-10","volume":"54","author":"Mortensen K.L.","year":"2010","unstructured":"Mortensen K.L.; Mellado E.; Lass-Fl\u00f6rl C.; Rodriguez-Tudela J.L.; Johansen H.K.; Arendrup M.C.; Environmental study of azole-resistant Aspergillus fumigatus and other aspergilli in Austria, Denmark, and Spain. Antimicrob Agents Chemother 2010,54(11),4545-4549","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=207","doi-asserted-by":"publisher","first-page":"2234","DOI":"10.3389\/fmicb.2018.02234","volume":"9","author":"Abdolrasouli A.","year":"2018","unstructured":"Abdolrasouli A.; Petrou M.A.; Park H.; Surveillance for Azole-Resistant Aspergillus fumigatus in a Centralized Diagnostic Mycology Service, London, United Kingdom, 1998-2017. Front Microbiol 2018,9,2234","journal-title":"Front Microbiol"},{"key":"ref=208","doi-asserted-by":"publisher","first-page":"516","DOI":"10.3389\/fmicb.2018.00516","volume":"9","author":"Zoran T.","year":"2018","unstructured":"Zoran T.; Sartori B.; Sappl L.; Azole-resistance in Aspergillus terreus and related species: An emerging problem or a rare phenomenon? Front Microbiol 2018,9,516","journal-title":"Front Microbiol"},{"key":"ref=209","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1164\/rccm.201612-2540LE","volume":"196","author":"van de Veerdonk F.L.","year":"2017","unstructured":"van de Veerdonk F.L.; Kolwijck E.; Lestrade P.P.A.; Influenza-associated aspergillosis in critically ill patients. Am J Respir Crit Care Med 2017,196(4),524-527","journal-title":"Am J Respir Crit Care Med"},{"key":"ref=210","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1111\/myc.12788","volume":"61","author":"Schauwvlieghe A.F.A.D.","year":"2018","unstructured":"Schauwvlieghe A.F.A.D.; de Jonge N.; van Dijk K.; The diagnosis and treatment of invasive aspergillosis in Dutch haematology units facing a rapidly increasing prevalence of azole-resistance. A nationwide survey and rationale for the DB-MSG 002 study protocol. Mycoses 2018,61(9),656-664","journal-title":"Mycoses"},{"key":"ref=211","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1097\/QCO.0000000000000005","volume":"26","author":"Vermeulen E.","year":"2013","unstructured":"Vermeulen E.; Lagrou K.; Verweij P.E.; Azole resistance in Aspergillus fumigatus: A growing public health concern. Curr Opin Infect Dis 2013,26(6),493-500","journal-title":"Curr Opin Infect Dis"},{"key":"ref=212","doi-asserted-by":"publisher","first-page":"4569","DOI":"10.1128\/AAC.00233-15","volume":"59","author":"Vermeulen E.","year":"2015","unstructured":"Vermeulen E.; Maertens J.; De Bel A.; Nationwide surveillance of azole resistance in Aspergillus diseases. Antimicrob Agents Chemother 2015,59(8),4569-4576","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=213","doi-asserted-by":"publisher","first-page":"S436","DOI":"10.1093\/infdis\/jix210","volume":"216","author":"Chowdhary A.","year":"2017","unstructured":"Chowdhary A.; Sharma C.; Meis J.F.; Azole-resistant aspergillosis: Epidemiology, molecular mechanisms, and treatment. J Infect Dis 2017,216(Suppl. 3),S436-S444","journal-title":"J Infect Dis"},{"key":"ref=214","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1002\/ps.3390","volume":"69","author":"Verweij P.E.","year":"2013","unstructured":"Verweij P.E.; Kema G.H.J.; Zwaan B.; Melchers W.J.G.; Triazole fungicides and the selection of resistance to medical triazoles in the opportunistic mould Aspergillus fumigatus. Pest Manag Sci 2013,69(2),165-170","journal-title":"Pest Manag Sci"},{"key":"ref=215","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.3201\/eid2106.140717","volume":"21","author":"van der Linden J.W.M.","year":"2015","unstructured":"van der Linden J.W.M.; Arendrup M.C.; Warris A.; Prospective multicenter international surveillance of azole resistance in Aspergillus fumigatus. Emerg Infect Dis 2015,21(6),1041-1044","journal-title":"Emerg Infect Dis"},{"key":"ref=216","doi-asserted-by":"publisher","first-page":"3380","DOI":"10.1128\/AAC.00383-13","volume":"57","author":"Alastruey-Izquierdo A.","year":"2013","unstructured":"Alastruey-Izquierdo A.; Mellado E.; Pel\u00e1ez T.; Population-based survey of filamentous fungi and antifungal resistance in Spain (FILPOP Study). Antimicrob Agents Chemother 2013,57(7),3380-3387","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Current Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1389450123666220623164548","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/206365\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1389450123666220623164548","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,11]],"date-time":"2022-12-11T07:32:18Z","timestamp":1670743938000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/206365\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":216,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1389450123666220623164548","relation":{},"ISSN":["1389-4501"],"issn-type":[{"value":"1389-4501","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2021-09-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-12","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}